Acute angle-closure glaucomaMANAGEMENT

OPHTHALMOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

548 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Acute angle-closure glaucoma Central retinal artery occlusion Central Retinal Vein Occlusion Chemical eye injury Corneal abrasion Corneal ulcer Globe rupture Hyphema Iritis-Uveitis Ocular foreign body Optic Neuritis Orbital cellulitis Orbital Floor Fracture (Blowout)Retinal detachment Vitreous Hemorrhage

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp37

Time-critical priorities

›Immediate stabilization

›Airway compromise from vomiting or altered mental status

›If aspiration risk, airway protection pathway

›If severe agitation, procedural sedation precautions

›Hemodynamic instability

›If shock, alternate diagnosis pathway

›If hypertensive emergency features, concurrent management

›Rapid pain and nausea control

›Antiemetic to enable oral therapy tolerance

›Analgesia without delaying ocular therapy

›Vision threat recognition

›Time-dependent risk of permanent vision loss

›Hours-to-days window for optic nerve ischemic injury

›Delay risk with normal neuro imaging

›Emergent ophthalmology involvement

›If not immediately available, initiate empiric IOP-lowering regimen

›Transfer to facility with urgent laser capability

Immediate triggers for escalation

›High-risk features

›Severe ocular pain with decreased vision

›Corneal haze with fixed mid-dilated pupil

›Headache with nausea or vomiting

›Very high intraocular pressure

›If IOP markedly elevated with corneal edema, immediate multi-agent therapy

›If IOP unavailable, treat based on classic exam

›Secondary angle closure concern

›If trauma, lens dislocation pathway

›If uveitis, inflammatory angle closure pathway

Monitoring and goals

›Therapeutic targets

›Intraocular pressure reduction to symptom relief and corneal clearing

›Recheck IOP after each therapy step when available

›If IOP remains high after maximal medical therapy, urgent hyperosmotic and procedure pathway

›Corneal clarity improvement

›Enables definitive gonioscopy and laser

›Reduces pain and photophobia

›Avoid worsening pupillary block

›Avoid mydriatic agents

›Avoid anticholinergic antiemetics when alternatives exist

02History/hx63

Presentation pattern

›Symptom profile

›Sudden unilateral eye pain

›Rapid vision decrease

›Halos around lights

›Headache

›Frontal or hemicranial

›Misdiagnosis as migraine risk

›Nausea and vomiting

›Prominent in acute attacks

›Dehydration from emesis complicating hyperosmotics

›Time course

›Onset to presentation interval

›Short interval typical for acute crisis

›Longer interval increases optic nerve injury risk

›Intermittent prior episodes

›Brief self-resolving blur and halos

›Preceding dark-room or stress trigger

Risk factors and triggers

›Anatomic and demographic risks

›Older age

›Lens thickening and shallow anterior chamber

›Higher prevalence after midlife

›Female sex

›Smaller ocular dimensions association

›Higher risk population pattern

›Hyperopia

›Short axial length and crowded angle

›Prior refraction history clue

›Medication and exposure triggers

›Anticholinergics

›Antihistamines

›Tricyclic antidepressants

›Sympathomimetics

›Decongestants

›Nebulized bronchodilators with anticholinergic effect

›Serotonergic agents with mydriasis risk

›SSRIs and SNRIs

›Triptans with pupillary effects

›Topical mydriatics

›Recent eye exam dilation

›Accidental exposure to dilating drops

Key context

›Ocular history

›Prior angle closure or narrow angles

›Prior laser peripheral iridotomy

›Prior recommendation for prophylaxis

›Prior glaucoma diagnosis

›Baseline drops and adherence

›Prior IOP history

›Recent ocular surgery

›Cataract surgery status

›Postoperative complications concern

›System history affecting therapy

›Asthma or COPD

›Beta-blocker drop contraindication risk

›Alternative topical pathway

›Heart block or bradycardia

›Timolol adverse effect risk

›Need for monitoring

›Sulfonamide allergy

›Acetazolamide risk assessment

›Alternative systemic pathway

›Renal failure or heart failure

›Hyperosmotic agent contraindication risk

›Fluid shifts monitoring

03Physical Exam/exam56

Eye and neuro-ophthalmic exam

›Visual function

›Visual acuity

›Baseline comparison if known

›If very poor acuity, urgent optic nerve risk

›Visual fields by confrontation

›Peripheral loss possible

›Limited by pain and corneal edema

›Pupils

›Mid-dilated pupil

›Poor reactivity

›Iris ischemia finding

›Relative afferent pupillary defect

›Suggests optic nerve compromise

›Incomplete exam if severe photophobia

›External and conjunctiva

›Conjunctival injection

›Ciliary flush pattern

›Chemosis possible

›Eyelid edema

›Reactive swelling

›Differential with cellulitis

Slit lamp and anterior segment findings

›Cornea

›Corneal edema

›Hazy cornea

›Epithelial microcysts

›Epithelial defects

›Fluorescein staining to exclude abrasion

›Contact lens associated keratitis alternate pathway

›Anterior chamber

›Shallow depth

›Van Herick peripheral depth reduction

›Asymmetric depth between eyes

›Cells and flare

›Uveitis consideration

›Secondary angle closure pathways

›Intraocular pressure

›Tonometry measurement

›Typically markedly elevated

›If cannot measure due to corneal edema, clinical diagnosis supported by classic triad

›Palpation estimate

›Rock-hard globe clue

›Used only when tonometry unavailable

System exam and pitfalls

›Neurologic screen

›Focal deficits

›If present, alternate intracranial process consideration

›Avoid anchoring on eye pain alone

›Meningismus

›If present, meningitis or SAH pathway

›Coexisting headache differential

›PITFALLS

›Migraine mimic

›Nausea and photophobia overlap

›Eye exam prevents missed diagnosis

›Red eye mislabeling

›Conjunctivitis misdiagnosis risk

›IOP and pupil check required in painful red eye

04Differential Diagnosis/ddx60

Vision-threatening differentials

›Acute angle-closure glaucoma

›Primary pupillary block crisis

›Shallow anterior chamber

›Mid-dilated fixed pupil

›Secondary angle closure

›Plateau iris configuration

›Lens-induced angle closure

›Optic neuritis

›Pain with eye movements

›Reduced color vision

›Relative afferent pupillary defect

›Normal or low IOP

›Clear cornea typical

›Fundus may be normal early

›Uveitis with secondary glaucoma

›Cells and flare

›Photophobia prominent

›Posterior synechiae possible

›IOP variable

›Can be elevated with trabeculitis

›Steroid response risk if treated empirically

Painful red eye mimics

›Corneal ulcer or keratitis

›Fluorescein uptake

›Contact lens risk

›Purulent discharge possible

›IOP usually normal

›Pupil usually reactive

›No shallow chamber

›Scleritis

›Deep boring pain

›Pain with palpation

›Autoimmune association

›Blanching response absent

›Phenylephrine test helpful when available

›Requires systemic workup

Headache and systemic mimic pathway

›Subarachnoid hemorrhage

›Thunderclap headache

›Neck stiffness

›Normal ocular exam typically

›Need for neuroimaging

›If clinical concern, do not delay workup

›Coexisting eye complaints uncommon

›Temporal arteritis

›Jaw claudication and scalp tenderness

›Elevated inflammatory markers

›Vision loss may be painless

›Age over 50

›Immediate steroid pathway

›Ophthalmology and rheumatology involvement

Coding

›ICD-10 diagnostic coding

›H40.21X0 acute angle-closure glaucoma unspecified eye

›Laterality code selection per documentation

›Use more specific H40.21X1 to H40.21X3 codes when vision stage recorded

›H40.20X0 angle-closure glaucoma unspecified eye

›Use when not clearly acute crisis

›Confirm acute vs chronic classification

›SNOMED CT concepts

›Acute angle-closure glaucoma

›Primary angle-closure glaucoma attack

›Secondary angle closure glaucoma

05Laboratory Tests/lt35

Baseline safety labs for systemic therapy

›Renal and electrolyte profile

›Creatinine and estimated GFR

›Acetazolamide dosing safety

›Hyperosmotic agent risk stratification

›Sodium and potassium

›Diuretic effect monitoring

›Vomiting-related derangements

›Glucose

›Diabetes risk with hyperosmotic oral agents

›Glycerol contraindication in diabetes

›Stress hyperglycemia recognition

›Altered mental status differential

›Hypoglycemia exclusion

›Hyperglycemia and dehydration overlap

Focused labs by comorbidity

›Pregnancy testing when relevant

›Medication safety planning

›Acetazolamide risk discussion

›Hyperosmotic agent fetal considerations

›Obstetric consultation triggers

›Severe hypertension features

›Hyperemesis overlap

›Cardiac evaluation support

›ECG for beta-blocker risk

›Heart block recognition

›Bradycardia baseline assessment

›BNP or troponin only if clinically indicated

›Heart failure concern before mannitol

›Not routine for isolated AACG

PITFALLS and limitations

›Laboratory role limits

›No lab confirms AACG

›Diagnosis is clinical plus IOP and angle assessment

›Over-reliance delays treatment

›Normal labs do not reduce urgency

›Vision threat persists

›Ophthalmology timing remains critical

06Diagnostic Tests/dt56

Scoring Systems

›Angle assessment grading

›Shaffer angle grading

›Grade 0 closed angle

›Grade 1 very narrow

›Van Herick method

›Peripheral chamber depth estimate

›Screening for narrow angles

›Disease classification frameworks

›Primary angle closure spectrum

›Primary angle closure suspect

›Primary angle closure

›Acute angle-closure crisis definition elements

›Symptoms with high IOP

›Closed angle on gonioscopy

MRI

›Neuroimaging indications

›Atypical presentation for AACG

›Normal eye exam with severe headache

›Persistent neurologic deficits

›Optic neuritis or orbital apex concern

›Pain with eye movements

›Color vision loss predominant

›Limitations for AACG

›Not a primary diagnostic test

›Does not replace tonometry and gonioscopy

›Delay harms vision outcomes

›Utility mainly for alternate diagnoses

›Intracranial pathology exclusion

›Orbital inflammatory processes

›Imaging indications

›Trauma with suspected globe or lens injury

›Lens dislocation mechanism

›Retrobulbar hemorrhage concern

›Severe headache with red flags

›Thunderclap onset

›Focal neurologic deficits

›Limitations for AACG

›Not diagnostic for angle closure

›Normal CT does not exclude AACG

›Eye exam remains decisive

›Avoid treatment delay

›Start IOP lowering before transport when safe

›Parallel workup for neuro red flags

Ultrasound

›Point-of-care ocular ultrasound roles

›Lens position assessment

›Lens subluxation or dislocation

›Secondary angle closure mechanism

›Posterior segment evaluation when cornea opaque

›Retinal detachment exclusion

›Vitreous hemorrhage assessment

›Ultrasound biomicroscopy and anterior segment imaging

›Plateau iris assessment

›Crowded angle despite iridotomy

›Mechanism clarification for definitive care

›Ciliary body and iris configuration

›Malignant glaucoma patterns

›Lens vault estimation

07Disposition/dispo28

Level of care decisions

›Admission or transfer criteria

›Acute angle-closure crisis diagnosis

›Requires urgent ophthalmology procedure planning

›Requires serial IOP monitoring

›Persistent elevated IOP after maximal therapy

›Hyperosmotic therapy requirement

›Urgent laser or surgical pathway

›Observation pathway

›Rapid response to therapy with stable exam

›IOP controlled and symptoms improved

›Ophthalmology bedside evaluation completed

›Access to urgent definitive therapy within hours

›Laser peripheral iridotomy scheduled same day

›Reliable follow-up and transport

Consultation and transfer logistics

›Ophthalmology consultation timing

›Immediate notification on suspicion

›Parallel initiation of IOP lowering therapy

›Avoid waiting for imaging

›Procedure planning

›Laser peripheral iridotomy affected eye

›Prophylactic iridotomy fellow eye

›Transfer triggers

›No tonometry or no ophthalmology availability

›Initiate empiric regimen prior to transfer

›Document exam findings and response

›Need for operating room intervention

›Unable to perform laser

›Cataract extraction or iridectomy plan

08Treatment/t83

Immediate medical therapy bundle

›Topical aqueous suppressants

›Timolol 0.5% 1 drop affected eye

›Repeat every 15 minutes for 2 to 3 doses

›Avoid in asthma or COPD with bronchospasm history

›Avoid in second or third degree AV block

›Brimonidine 0.1% to 0.2% 1 drop affected eye

›Repeat every 15 minutes for 2 to 3 doses

›Avoid in infants due to apnea risk

›Caution with hypotension and sedation

›Dorzolamide 2% 1 drop affected eye

›Repeat every 15 minutes for 2 to 3 doses

›Sulfonamide-related reaction caution

›Additive effect with systemic acetazolamide

›Systemic carbonic anhydrase inhibition

›Acetazolamide 500 mg IV once

›Alternative 500 mg PO once if tolerating oral intake

›Follow with 250 mg PO every 6 hours

›Avoid in severe renal impairment

›Acetazolamide contraindication alternatives

›Methazolamide PO when available

›Early hyperosmotic agent with ophthalmology guidance

Miotic therapy timing and selection

›Pilocarpine strategy

›Pilocarpine 1% to 2% 1 drop affected eye

›Use after IOP reduced below 40 mmHg

›Repeat every 15 minutes for 2 doses

›Corneal edema may limit penetration

›Pilocarpine pitfalls

›Ineffective at very high IOP due to iris sphincter ischemia

›Avoid early use when IOP very high

›Avoid if mechanism not pupillary block until ophthalmology confirms

Hyperosmotic therapy for refractory elevation

›Mannitol IV

›Mannitol 0.5 g/kg IV over 20 to 60 minutes

›Alternative up to 1 to 2 g/kg per protocol and tolerance

›Strict fluid status monitoring

›Serum osmolality monitoring when repeated doses used

›Mannitol contraindications and precautions

›Heart failure and pulmonary edema risk

›Severe renal impairment risk

›Hypotension and electrolyte shifts monitoring

›Oral hyperosmotics when appropriate

›Isosorbide 45% solution 220 mL PO once

›Avoid in severe dehydration

›Monitor nausea and vomiting

›Consider glucose effect in diabetes

›Glycerol 1 mL/kg PO diluted with equal volume water

›Contraindicated in diabetes

›Significant nausea risk

›Use only with ophthalmology guidance

Supportive and adjunct care

›Symptom control

›Ondansetron 4 mg IV or PO

›Repeat per nausea control protocol

›Enables oral acetazolamide if needed

›Analgesia

›Acetaminophen PO or IV per weight

›Opioid analgesia if severe pain with monitoring

›Medication avoidance

›Avoid anticholinergic antiemetics when possible

›Mydriasis risk worsening closure

›Use non-anticholinergic alternatives

›Avoid topical mydriatics

›Worsens pupillary block

›Confounds ophthalmology exam

Definitive therapy and follow-through

›Laser peripheral iridotomy

›Affected eye after corneal clearing

›Definitive relief for pupillary block mechanism

›Prevents recurrence

›Fellow eye prophylaxis

›High risk of future acute attack

›Timing per ophthalmology

›Surgical options when laser not feasible

›Surgical iridectomy

›For failed laser or corneal edema preventing laser

›Often combined with lens-based interventions

›Lens extraction pathway

›Phacomorphic angle closure

›Cataract contributing to crowding

Evidence framing for emergency practice

›Guideline strength interpretation

›Strong consensus for immediate IOP lowering prior to definitive iridotomy

›Analogous to Class I recommendation in time-critical care pathways

›Based on ophthalmology society guidance and standard emergency practice

›Evidence grading note

›ACEP-specific A B C levels not routinely published for AACG

›Use local emergency eye guidelines and ophthalmology society guidance for protocoling

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Maternal vision threat prioritization

›Immediate ophthalmology involvement

›Shared decision-making for systemic agents

›Medication safety

›Acetazolamide risk discussion and obstetric consultation

›Prefer topical therapy when effective

›Hyperosmotic agent caution

›Avoid dehydration and hypotension

›Fetal perfusion considerations with osmotic shifts

Geriatric

›Older adult considerations

›Higher baseline narrow angle prevalence

›Lens thickening and shallow chamber

›Higher recurrence risk without definitive therapy

›Comorbidity impact on drops

›Beta-blocker systemic effects

›Bradycardia and hypotension monitoring

›Renal and cardiac reserve limits

›Acetazolamide dosing adjustment and avoidance

›Mannitol pulmonary edema risk

Pediatrics

›Pediatric considerations

›Rarity of acute primary angle closure

›Secondary causes more likely

›Congenital anomalies and syndromes consideration

›Medication safety

›Brimonidine avoidance in infants and young children

›Weight-based systemic dosing for hyperosmotics

›Specialist urgency

›Pediatric ophthalmology consultation

›Lower threshold for imaging if trauma or mass concern

10Background/b45

Epidemiology

›Population patterns

›Less common than open-angle glaucoma but more likely to cause sudden severe vision loss

›High morbidity without rapid intervention

›Emergency presentation pattern

›Higher risk in older adults and females

›Smaller anterior segment dimensions association

›Age-related lens changes association

›Anatomical predisposition

›Shallow anterior chamber

›Hyperopia association

›Crowded anterior segment

Pathophysiology

›Primary pupillary block mechanism

›Iris-lens apposition increased resistance to aqueous flow

›Posterior chamber pressure rise

›Iris bombe and angle closure

›Trabecular meshwork obstruction

›Rapid IOP rise

›Corneal edema and pain

›Secondary angle closure mechanisms

›Plateau iris

›Anteriorly positioned ciliary body

›Persistent narrow angle after iridotomy

›Lens-induced angle closure

›Phacomorphic crowding

›Lens subluxation and forward shift

Therapeutic Considerations

›Treatment rationale by class

›Beta-blockers and alpha agonists reduce aqueous production

›Rapid onset in acute setting

›Additive effect in combination

›Carbonic anhydrase inhibitors reduce aqueous production systemically and topically

›Fast systemic effect with IV dosing

›Electrolyte and renal considerations

›Miotics reverse pupillary block after IOP reduction

›Requires viable iris sphincter

›Reduced efficacy when IOP very high

›Hyperosmotics reduce vitreous volume and IOP

›Bridge to definitive laser or surgery

›Significant systemic risk in cardiac and renal disease

›Definitive therapy rationale

›Iridotomy creates alternate aqueous pathway

›Resolves pupillary block mechanism

›Prevents recurrence

›Fellow-eye prophylaxis rationale

›Shared anatomic predisposition

›Prevents future acute crisis

11Patient Discharge Instructions/pdi34

copy discharge instructions

›Discharge criteria framework

›Only after ophthalmology evaluation and plan

›Definitive therapy completed or scheduled urgently

›IOP controlled and symptoms improved

›Medication plan and technique

›Eye drop schedule written and reviewed

›Punctal occlusion technique to reduce systemic absorption

›Return to emergency criteria

›Recurrent severe eye pain

›Sudden vision decrease

›Halos with headache or vomiting

›Worsening redness or photophobia

›Concern for uveitis or keratitis

›New discharge or corneal opacity

›Medication adverse effects

›Wheezing or shortness of breath after timolol

›Fainting or severe dizziness

›Neurologic red flags

›Thunderclap headache

›New weakness or speech change

›Activity and trigger avoidance

›Avoid over-the-counter decongestants and anticholinergics unless cleared

›Medication list review at follow-up

›Pharmacy counseling recommendation

›Avoid pupil dilation until ophthalmology cleared

›No mydriatic drops

›Inform all clinicians of narrow-angle history

›Follow-up

›Ophthalmology follow-up within 24 to 72 hours or per plan

›Confirm iridotomy patency when performed

›Gonioscopy and definitive mechanism assessment

›Fellow eye evaluation

›Prophylactic iridotomy planning

›Narrow angle risk counseling

12References/r21

Clinical guidelines and core sources

›Ophthalmology society guidance

›American Academy of Ophthalmology Preferred Practice Pattern for primary angle closure and angle-closure glaucoma

›Medical IOP reduction prior to definitive procedure

›Laser peripheral iridotomy as definitive management for pupillary block

›Royal College of Ophthalmologists guideline for management of angle-closure glaucoma

›Systemic acetazolamide and topical agents as first-line in acute attack

›Definitive iridotomy and fellow eye prophylaxis principles

›Emergency and general references

›Merck Manual Professional Edition angle-closure glaucoma regimen summary

›Timolol brimonidine pilocarpine acetazolamide sequencing

›Hyperosmotic agent options for refractory IOP

›NCBI Bookshelf StatPearls acute angle-closure glaucoma

›Pilocarpine use after IOP below 40 mmHg

›Mechanism explanation and differential diagnosis

›Practice summaries and review articles

›EmergencyCareBC acute angle-closure glaucoma clinical summary

›ED drop sequence and systemic dosing

›Mannitol dosing range for inadequate response

›Peer-reviewed review on emergency management of angle closure

›Hyperosmotic agent cautions in cardiac and renal disease

›Risks of diabetes with glycerol

Learn More: Acute angle-closure glaucoma→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.